Monoclonal antibodies have arrived as therapeutics, and in some cases have become an integral part of standard treatment, as exemplified by Herceptin and Remicade. The global monoclonal antibodies market, worth $30bn in 2009, remains one of the most exciting and promising areas within the world pharmaceutical market today.
From inauspicious beginnings in the 1980s, monoclonal antibodies have now become the most successful class of biotech drugs in history, with 21 FDA approved therapies and eight blockbusters currently in use. Technological advances have dramatically reduced their immunogenicity and current, third generation mAbs, have clinical utility ranging across molecular diagnostics, to oncology and infectious diseases.
The next 20 years promise to be equally exciting, with 200 products in the pipeline and a projected growth rate of 13%. Looking to this future, Visiongain focuses its fifth monoclonal antibodies conference on the main growth areas in the years ahead: solid and liquid tumours, autoimmune and infl ammatory diseases and fully human mAbs. With an expert line-up of speakers from around the world, this two-day event is an ideal forum for investors and scientists alike wishing to engage with, and explore, prospects for fourth generation mAbs.
By attending this conference, you will gain key insights into the hottest topics and main drivers in mAb research and development today, including:
• Moving towards fully human and tailor made antibody therapeutics
• The importance of isotyping in preclinical modelling
• New data from clinical trials for conjugated and unconjugated therapies
• Identifying and validating cell-surface antigens for antibody targeting
• Prospects for fragment monoclonal antibodies
• Overcoming immune reactions to improve clinical applications of antibody therapeutics
• Reducing infl ammation and tissue damage in central nervous system diseases
• Targeting deregulated cell-signalling pathways
• Prospects for inhibiting angiogenesis
• Perspectives on antibody process development including sharing IP, or implementing and licensing commercial process technologies
Key Speakers you will meet there include:
• Janice Reichert, Senior Research Fellow, Tufts University, and Editor-in-Chief, mAbs
• John Birch, Chief Scientific Officer, Lonza
• Andy Popplewell, Director, V-Region Discovery & Engineering, UCB Celltech
• Bo Kara, Director, Science and Technology, Avecia Biologics
• David Lowe, Head of Display Technology, MedImmune
• Zehra Kaymakcalan, Senior Principal Scientist, Biologics Research Centre, Abbott Laboratories
• Steve England, Associate Research Fellow, Pfizer
5th Annual Monoclonal Antibodies
Advancing therapeutic antibody development and production
24th - 25th March 2009, London, UK
http://www.visiongain.com/
To Book: All you need to register is contact Suvitha.
You can either call on TEL:+44(0)2075499946
or email:suvitha.damodaran@
